Statement Of Investor Complaints For The Quarter Ended June 30, 2017
Pursuant to Regulation 13 (3) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find below the statement of Investor complaints for the quarter ended June 30, 2017. Glenmark Pharma Gets USFDA Nod For Hypertension Medicine
According to IMS Health sales data for the 12 months to May 2017, Azor tablets achieved annual sales of approximately $211.6 million, Glenmark said. Press Release
Sub:- Glenmark Pharmaceuticals Receives ANDA approval For Amlodipine and Olmesartan Medoxomil Tablets, 5 mg/20 mg, 5 mg/40 mg, 10 mg/20 mg, and 10 mg/40 mg With reference to the subject mentioned above, kindly find attached media release which is self-explanatory. Request you to kindly take the same on record. Glenmark gets MHRA nod for OTC sale of anti-malarial drug
Glenmark Pharma today said that the UK drug regulator MHRA has granted final approval to Glenmark Pharmaceuticals Europe for anti-malarial medication Maloff Protect' as a pharmacy licence in the... Press Release
Sub:- Glenmark Pharmaceuticals receives MHRA, UK approval for Maloff Protect, anti-malarial medication as a Pharmacy license in the UK With reference to the subject mentioned above, kindly find attached media release which is self-explanatory. Request you to kindly take the same on record. Glenmark gets USFDA nod for generic anti-inflammatory drug
Glenmark Pharmaceuticals has received final approval from the US health regulator for its generic version of anti-inflammatory drug Indomethacin tablets. The approval granted to Glenmark... Press Release
Dear Sirs, Sub:- Glenmark Pharmaceuticals receives ANDA Approval for Indomethacin Extended-Release Capsules USP, 75 mg With reference to the subject mentioned above, kindly find attached media release which is self-explanatory. Request you to kindly take the same on record. US FDA approves Glenmark Pharma's drug for overactive bladder
The scrip was trading 0.79 per cent higher at Rs 633.65 on the BSE Press Release
Dear Sirs, Sub:- Glenmark Pharmaceuticals Receives Tentative ANDA Approval For Solifenacin Succinate Tablets, 5 mg and 10 mg With reference to the subject mentioned above, kindly find attached media release which is self-explanatory. Request you to kindly take the same on record. Press Release
Dear Sirs, Sub:- Glenmark Pharmaceuticals Licenses Small Molecule Oncology Compound from APC Therapeutics to Expand Immuno-Oncology Portfolio With reference to the subject mentioned above, kindly find attached media release which is self-explanatory. Request you to kindly take the same on record.